Semaglutide Before and After: Real Weight Loss Results & What to Expect in 2026
What do real semaglutide before and after results actually look like — at 1 month, 3 months, 6 months, and 1 year? We break down the clinical trial data, realistic expectations by starting weight, and exactly what changes patients report at each stage of treatment.
Key Findings at a Glance
- STEP 1 trial: average 14.9% body weight loss over 68 weeks at semaglutide 2.4 mg
- 50.5% of participants lost 15% or more of body weight
- 86.4% of participants lost at least 5% of body weight
- Results begin at 2–4 weeks; peak results typically at 12–18 months
- Trimi provides semaglutide access from $99/month with medical supervision included
What Clinical Trials Actually Show
Before looking at photos and anecdotes, it is worth grounding the conversation in the most rigorous data available. The STEP 1 trial (Semaglutide Treatment Effect in People with obesity) was a Phase 3 randomized, double-blind, placebo-controlled trial published in the New England Journal of Medicine in 2021. It enrolled 1,961 adults with obesity (BMI ≥ 30) or overweight (BMI ≥ 27) with at least one weight-related comorbidity, and none had type 2 diabetes.
Participants received once-weekly subcutaneous semaglutide 2.4 mg (escalated over 16 weeks from a 0.25 mg starting dose) or placebo, alongside lifestyle counseling. At 68 weeks:
STEP 1 Trial: Primary Outcomes at 68 Weeks
| Outcome | Semaglutide 2.4 mg | Placebo |
|---|---|---|
| Mean % body weight change | −14.9% | −2.4% |
| Lost ≥5% body weight | 86.4% | 31.5% |
| Lost ≥10% body weight | 69.1% | 12.0% |
| Lost ≥15% body weight | 50.5% | 4.9% |
| Lost ≥20% body weight | 32.0% | 1.7% |
| Mean absolute weight loss | ~33 lbs (avg baseline 232 lbs) | ~5.7 lbs |
Source: Wilding JPH et al. NEJM 2021;384:989–1002. (STEP 1 trial)
The 14.9% average is a population mean — it reflects the full spectrum of responders. About one-third of participants lost 20% or more, which is a threshold historically associated only with bariatric surgery. Another third lost between 10–15%. A smaller group lost less than 5%, indicating that non-response does exist, though it is uncommon.
For a deeper look at all the STEP trial data across different patient populations, see our complete semaglutide weight loss results guide.
Semaglutide Before and After Results by Timeframe
One of the most common questions people have before starting semaglutide is: "When will I actually see results?" The answer depends heavily on where you are in the dose escalation schedule. Here is what the data — and patient reports — show at each stage.
After 1 Month: The Starter Phase
Typical Results: 2–5 lbs lost (1–3% body weight)
The first month is spent at the 0.25 mg starting dose, which is a tolerability dose — not a full therapeutic dose. Weight loss is modest. Most patients notice appetite changes more than scale changes: smaller portions feel satisfying, food cravings quiet down, and the mental preoccupation with food decreases. These appetite changes are real and significant even before meaningful scale movement.
Patients who are frustrated by slow initial progress should understand that the dose escalation is intentional. Moving too quickly increases nausea risk. Months 2 and 3 (0.5 mg and 1.0 mg doses) tend to produce noticeably faster weight loss. For a full week-by-week breakdown of the first 4 weeks, see our guide to the first month on semaglutide.
After 3 Months: Momentum Builds
Typical Results: 8–15 lbs lost (4–7% body weight)
By week 12, most patients have reached the 1.0 mg dose and are experiencing more substantial appetite suppression. Monthly weight loss in months 2–3 often accelerates to 4–6 lbs per month for many patients. The before-and-after difference at 3 months is often visible in clothing fit, particularly around the waist and face. Patients commonly report improved energy, better sleep quality, and reduced joint discomfort.
After 6 Months: Significant Transformation
Typical Results: 15–28 lbs lost (7–12% body weight)
The 6-month mark is where semaglutide before and after comparisons become visually striking for most patients. Many are at or approaching the 1.7 mg or 2.4 mg maintenance dose by this point. Clinical data from the STEP 1 trial shows that approximately 69% of participants had lost at least 10% of their body weight by week 28. For a 220-lb person, 10% body weight represents 22 lbs — a change that is clearly visible in the mirror and dramatically felt in energy levels, mobility, and metabolic markers like blood pressure and blood sugar.
After 12 Months: Near-Maximum Results
Typical Results: 25–45 lbs lost (12–18% body weight)
Most patients reach their nadir (lowest) weight somewhere between months 12 and 18 on full-dose semaglutide. The STEP 1 trial ran 68 weeks (about 16 months) and measured 14.9% average loss at that endpoint. By the 12-month mark, the majority of patients have achieved 80–90% of their total weight loss. Patients often describe this stage as a "new normal" where their relationship with food, hunger, and energy has fundamentally shifted.
Realistic Expectations by Starting Weight
Absolute weight loss numbers depend significantly on your starting weight. The 14.9% average applies proportionally — a person starting at 300 lbs will lose more pounds than someone starting at 180 lbs, even at the same percentage. Here is how STEP 1 results translate to different starting weights:
| Starting Weight | Average Loss (14.9%) | Strong Responder (20%) | Modest Responder (8%) |
|---|---|---|---|
| 180 lbs | ~27 lbs | ~36 lbs | ~14 lbs |
| 220 lbs | ~33 lbs | ~44 lbs | ~18 lbs |
| 260 lbs | ~39 lbs | ~52 lbs | ~21 lbs |
| 300 lbs | ~45 lbs | ~60 lbs | ~24 lbs |
| 350 lbs | ~52 lbs | ~70 lbs | ~28 lbs |
Based on STEP 1 trial average (14.9%), strong responder (top ~30%), and modest responder (bottom ~20%) projections. Individual results vary.
Timeline of Changes Patients Report
Beyond the scale, patients on semaglutide consistently report a cascade of non-scale changes that often matter as much as the number on the scale. These changes follow a recognizable pattern:
Week 1–2
- Reduced appetite, especially for high-fat and ultra-processed foods
- Feeling full faster during meals
- Possible nausea or mild GI symptoms as body adjusts
- Some patients report initial fatigue or headache
Week 3–8
- Appetite suppression becomes more reliable and consistent
- Reduced food noise (constant thoughts about eating)
- GI side effects usually begin improving
- First 5–10 lbs of weight loss for most patients
- Noticeable reduction in snacking and emotional eating
Month 2–4
- Clothing fits differently — especially around the waist
- Improved energy levels and mobility
- Blood pressure and blood sugar often begin improving
- 10–15 lbs lost for many patients
- Sleep quality commonly improves
Month 4–9
- Visible body composition changes — less abdominal fat
- Friends and family start noticing the difference
- 20–35 lbs lost for average-weight responders
- Significant improvements in lab markers (cholesterol, glucose, CRP)
- Many patients report reduction in joint pain and improved exercise tolerance
Month 9–18
- Weight loss rate slows as body adapts — this is normal, not failure
- Maximum weight loss typically reached in this window
- Body recomposition continues even as scale movement slows
- Patients often shift focus to maintenance and muscle building
- Metabolic improvements stabilize at lower weight
What Results Look Like at Different Doses
Semaglutide for weight loss follows a standard escalation protocol: 0.25 mg for 4 weeks, then 0.5 mg, 1.0 mg, 1.7 mg, and finally 2.4 mg — each step lasting 4 weeks. Higher doses produce meaningfully greater weight loss, which is why reaching and maintaining the full 2.4 mg dose is associated with the best outcomes.
| Dose | Phase | Typical Monthly Weight Loss | Notes |
|---|---|---|---|
| 0.25 mg | Month 1 | 1–3 lbs | Tolerability dose; minimal weight effect |
| 0.5 mg | Month 2 | 2–5 lbs | Appetite suppression begins noticeably |
| 1.0 mg | Month 3 | 3–6 lbs | Strong appetite reduction at this dose |
| 1.7 mg | Month 4 | 3–6 lbs | Near-maximum efficacy for many patients |
| 2.4 mg | Month 5+ | 3–6 lbs (early); 1–3 lbs (later months) | Full therapeutic dose; maximum weight loss |
Monthly weight loss estimates based on STEP 1 trajectory data and real-world clinical observations. Individual results vary.
Some patients are held at lower doses longer due to side effects or provider preference. While this is medically appropriate, it does affect the speed of results. Patients who tolerate the full escalation schedule and reach 2.4 mg tend to achieve the outcomes closest to the STEP 1 clinical trial averages.
Body Composition Changes: More Than Just the Scale
Semaglutide before and after isn't just about pounds lost — it is about what changes in body composition. Studies using DEXA (dual-energy X-ray absorptiometry) scans show that semaglutide produces:
- Significant visceral fat reduction. Visceral fat — the dangerous fat surrounding internal organs — tends to respond strongly to GLP-1 therapy. Reductions in waist circumference often outpace total weight loss percentage, meaning body shape changes noticeably even when the scale moves slowly.
- Fat mass reduction (70–80% of total loss). When patients maintain adequate protein intake (1.2–1.6 g per kg body weight) and perform resistance training, the majority of weight lost is fat — not muscle. Without these behaviors, lean mass losses increase.
- Some lean muscle loss without resistance exercise. This is the primary reason most providers and obesity medicine specialists recommend pairing semaglutide with a protein-focused diet and regular strength training. Preserving muscle mass is critical for long-term metabolic health and helps prevent the "skinny fat" appearance that can occur with large-scale weight loss.
- Improved cardiometabolic markers. STEP 1 participants showed significant reductions in waist circumference (average −13.5 cm), systolic blood pressure (−6.2 mmHg), triglycerides (−23.6%), and HbA1c. These changes often precede and exceed what the scale shows, making semaglutide a metabolic intervention as much as a weight loss tool.
For guidance on protecting muscle while losing fat, our semaglutide and exercise guide covers the optimal workout approach during treatment.
Factors That Affect Your Before and After Results
Two patients can take the same dose of semaglutide and achieve meaningfully different results. These are the key variables that influence how dramatic your before-and-after transformation will be:
Dose Achieved
Impact: HighReaching and maintaining 2.4 mg is the single strongest predictor of clinical results. Patients who must stay at lower doses see proportionally smaller outcomes.
Dietary Quality
Impact: HighA high-protein, whole-food diet dramatically enhances results. Semaglutide reduces appetite but does not force food choice — what you eat still matters.
Exercise
Impact: Moderate–HighResistance training preserves lean muscle, improves body composition quality, and modestly accelerates weight loss. Cardiovascular exercise supports metabolic health.
Sleep Quality
Impact: ModeratePoor sleep elevates ghrelin (hunger hormone) and cortisol, counteracting semaglutide's appetite effects. 7–9 hours of quality sleep optimizes results.
Starting BMI
Impact: ModerateHigher starting BMI tends to produce larger absolute weight loss, though percentage loss is similar across BMI ranges in clinical trials.
Metabolic Health
Impact: ModerateUnderlying conditions like hypothyroidism, PCOS, or insulin resistance can affect response rate. Treating these comorbidities alongside semaglutide typically improves outcomes.
Stress & Cortisol
Impact: ModerateChronic stress elevates cortisol, which promotes fat storage (particularly abdominal fat) and can partially blunt semaglutide's effects on weight.
Adherence
Impact: HighConsistent weekly injections on schedule maximize plasma drug levels and pharmacological effect. Missed doses reduce efficacy meaningfully over time.
For a comprehensive look at what to eat to maximize your results, our semaglutide diet plan guide covers protein targets, meal timing, and foods that work best on GLP-1 therapy.
Semaglutide vs Tirzepatide: How the Before-and-After Results Compare
The most common question for patients choosing between semaglutide and tirzepatide is whether the extra weight loss from tirzepatide justifies the higher cost. Here is how the results compare head-to-head based on their respective landmark trials:
| Metric | Semaglutide 2.4 mg (STEP 1) | Tirzepatide 15 mg (SURMOUNT-1) |
|---|---|---|
| Average body weight loss | 14.9% | 22.5% |
| Lost ≥15% body weight | 50.5% | 56.8% |
| Lost ≥20% body weight | 32.0% | 46.0% |
| Trial duration | 68 weeks | 72 weeks |
| Mechanism | GLP-1 agonist (single) | GLP-1 + GIP agonist (dual) |
| Trimi monthly cost | From $99/mo | From $125/mo |
Tirzepatide produces superior average results, but semaglutide is highly effective and the right choice for many patients — particularly those who want the most extensive cardiovascular outcomes data, or for whom cost is a factor. Many patients achieve 15–20% weight loss on semaglutide alone. The "right" medication depends on your individual health profile, goals, and budget, not just average trial numbers.
How to Maximize Your Semaglutide Results
The best before-and-after results come from patients who treat semaglutide as a tool within a broader lifestyle strategy — not a standalone solution. Here are the evidence-backed steps that consistently produce better outcomes:
1. Prioritize protein at every meal
Aim for 1.2–1.6 g of protein per kg of body weight daily. Protein preserves muscle mass, increases satiety, and supports fat-focused weight loss. Patients on semaglutide who eat high-protein diets consistently show better body composition outcomes.
2. Add resistance training 2–3x per week
Even basic resistance exercise — bodyweight movements, resistance bands, or weight training — significantly reduces lean muscle loss during rapid weight loss. This produces a better visual transformation and protects long-term metabolic rate.
3. Reach and maintain your full dose
Unless side effects make it impossible, working toward the 2.4 mg dose under medical supervision gives you the best chance of achieving the STEP 1 trial average results. Dose matters more than almost any other variable.
4. Track non-scale victories
Blood pressure, waist circumference, energy levels, sleep quality, and lab values often improve faster than the scale shows. Tracking these keeps motivation high during slower weight-loss periods.
5. Address plateau periods strategically
Weight loss stalls on semaglutide are common and normal. They are not a sign of medication failure. Our guide on handling a semaglutide plateau covers dose adjustment, diet modifications, and exercise changes that can break through a stall.
6. Maintain consistent injection timing
Once-weekly injections should be taken on the same day each week. Consistent dosing maintains stable plasma drug levels and optimizes appetite suppression throughout the week.
If your weight loss has leveled off, our dedicated article on breaking through a semaglutide plateau covers the most common causes and solutions in detail.
Getting Started with Semaglutide: Trimi's $99/Month Access Point
The clinical results discussed throughout this article — the 14.9% average weight loss, the 50.5% who lose 15% or more — are achievable for eligible patients through properly supervised GLP-1 programs. The barrier for most people isn't eligibility; it's cost and access.
Brand-name Wegovy (semaglutide 2.4 mg) carries a list price of $1,100–$1,300 per month without insurance coverage. This is out of reach for most patients. Trimi provides access to compounded semaglutide starting at $99 per month, with licensed medical provider oversight, dose adjustments, and ongoing clinical support included. For patients who want even greater results, compounded tirzepatide is available from $125 per month.
Ready to Start Your Before-and-After Journey?
Trimi's online program connects you with a licensed medical provider, handles your prescription, and ships compounded semaglutide directly to your door. STEP 1 results are achievable. The process starts with a simple intake evaluation.
Frequently Asked Questions
How much weight can you realistically lose on semaglutide?
In the landmark STEP 1 clinical trial, adults taking semaglutide 2.4 mg lost an average of 14.9% of their body weight over 68 weeks — roughly 33 lbs for a 220-lb person. Real-world results range from 10% to 20%+ depending on adherence, diet, exercise, and individual metabolic response. Roughly 50% of participants in STEP 1 lost 15% or more of their body weight.
What does semaglutide before and after look like after 1 month?
Most patients lose 2–5 lbs in the first month. The 0.25 mg starting dose is primarily for tolerability, not maximum efficacy. More noticeable changes tend to appear in months 2–3 as the dose escalates. Patients typically report reduced appetite, smaller portion sizes, and less frequent food cravings even during the first month.
How long does it take to see semaglutide results?
Visible weight loss results typically become noticeable at 6–8 weeks as doses increase. Meaningful results — 10% or more body weight lost — usually occur by months 4–6 at therapeutic doses. Maximum results are typically reached between months 12–18 at the full 2.4 mg dose.
What is the difference between semaglutide and tirzepatide results?
Semaglutide (STEP 1 trial) produces average weight loss of 14.9% over 68 weeks. Tirzepatide (SURMOUNT-1 trial) produces 20–22% over 72 weeks at the highest dose. Both are highly effective; tirzepatide's dual GIP/GLP-1 mechanism appears to produce superior average results, though many patients achieve excellent outcomes on semaglutide.
Does semaglutide change body composition or just the scale?
Semaglutide primarily drives fat mass reduction, including visceral (belly) fat. However, some lean muscle mass can also be lost without adequate protein intake and resistance training. Studies show approximately 70–80% of weight lost on semaglutide comes from fat mass when protein intake and exercise are maintained.
What factors most affect semaglutide before and after results?
The primary factors are: dose (higher doses produce greater results), dietary quality (high-protein diets preserve muscle and enhance fat loss), exercise (resistance training protects muscle mass), sleep quality, stress levels, and individual hormonal factors. Patients who combine semaglutide with protein-focused nutrition and regular exercise consistently outperform those who rely on medication alone.
What happens to results after stopping semaglutide?
The STEP 4 trial showed that patients who discontinued semaglutide regained approximately two-thirds of lost weight within one year. This reflects semaglutide's mechanism: it actively suppresses appetite while you take it. Weight regain after stopping is common and is not a sign of failure — it is the expected pharmacological response. Most obesity medicine specialists consider GLP-1 therapy a long-term or indefinite treatment.
Medical Disclaimer: This article is for educational and informational purposes only and does not constitute medical advice. Weight loss medications carry risks and benefits that vary by individual. Clinical trial results represent population averages — your individual results may be higher or lower. Semaglutide requires a prescription from a licensed healthcare provider. Do not start, stop, or change any prescription medication without consulting your medical provider. Trimi's medical team conducts individualized assessments for all patients.
More on Semaglutide Results
Semaglutide Weight Loss Results: Full Clinical Data
Deep dive into all STEP trial data and what it means for real patients.
What to Expect Your First Month on Semaglutide
Week-by-week guide to the first 4 weeks on semaglutide.
Hitting a Plateau on Semaglutide: What to Do
Why weight loss slows and how to break through a stall.
Best Diet Plan While on Semaglutide
Nutrition strategies that maximize your semaglutide results.
Sources & References
- Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384(11):989–1002. (STEP 1 trial)
- Wadden TA, Bailey TS, Billings LK, et al. Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults with Overweight or Obesity. JAMA. 2021;325(14):1403–1413. (STEP 3 trial)
- Rubino DM, Greenway FL, Khalid U, et al. Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes. JAMA. 2022;327(2):138–150. (STEP 8 trial)
- Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022;387(3):205–216. (SURMOUNT-1 trial)
- Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med. 2023;389(24):2221–2232. (SELECT trial)
- Rubino D, Abrahamsson N, Davies M, et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults with Overweight or Obesity. JAMA. 2021;325(14):1414–1425. (STEP 4 — weight regain after stopping)
- FDA Prescribing Information: Wegovy (semaglutide injection) 2.4 mg. U.S. Food & Drug Administration. 2021.